Third quarter 2026 earnings call, November 9, 2026: management lifts margin and profit guidance, holds the revenue range but flags the low end, and sizes PAMA at a mid-single-digit 2027 headwind
A Deliberate Choice to Slow Genome Volume
The central new development on GeneDx's third quarter call is that management chose to throttle genome throughput in exchange for better payment. In Q3, the company changed genome workflows to collect payer-required documentation before testing begins in the lab. The cost was visible in the volume line. Accessions grew 28% year over year, while reported volume grew 25%. President Mark Gardner said the friction produced "higher rates of order cancellations, downgrades, and delayed starts."
The company now expects full-year exome and genome volume growth of at least 28%, with exome and genome revenue growth of at least 17%. Management framed the guide-down as a timing issue rather than lost demand. Chief Financial Officer Kevin Feeley said "substantially all" of the roughly 3-point gap between accessions and reported volume should pull through, though not in a single quarter. Gardner went further on the cancellations that are permanent, arguing that "in many cases, that's not necessarily great volume because we're unlikely to actually get paid for it."
Investors should note the limits of this explanation. Gardner said the workflow changes were implemented at the start of the quarter, which answered a Guggenheim question about why softness was not flagged earlier but also means the full effect is still being learned. Tycho Peterson of Jefferies asked what had changed since August guidance, and the answer was essentially that new revenue cycle, market access and finance leaders validated the plan and exposed the throughput constraint. Management acknowledged it is running several transformations at once: commercial expansion, new products and a mid-year revenue cycle overhaul. Feeley described the new posture as a "premium on paid volume as the goal rather than volume at all costs."
The impact is concentrated among geneticists, who are most likely to order genomes. Management conceded that the Foundational segment, which had been tracking toward high-20s volume growth, is likely running somewhat below that level.
Reimbursement Is Improving, but Through Mix as Much as Collections
The payoff so far is in average reimbursement rate (ARR), which rose about 5% sequentially to $3,436 from $3,258. Management guides to roughly $3,500 in Q4. Underlying like-for-like contract rates were "relatively unchanged," so the gain came from collections and mix rather than pricing.
The outpatient genome collection rate rose to 36% from 32%, a 400 basis point gain management attributes to early revenue cycle workflows, partly to Carelon's policy expansion to about 56 million lives, and only marginally to Medi-Cal. Exome collection was flat at roughly 32%. Genome's share of outpatient insurance-based volume fell to 26% from 32% in Q2, and was around 40% earlier in the year. Management called this "purposeful mix management," since exome carries both a higher contracted rate and a higher average reimbursement rate. William Bonello of Craig-Hallum pressed on whether part of the ARR gain simply reflects no longer billing tests that previously collected nothing. Gardner partly conceded the point: some tests run would never have been reimbursed regardless of administrative quality.
Gardner offered a useful diagnostic on denials. Management found that 62% of exome and genome denials were administrative and procedural, and therefore addressable through execution. The remaining 38% involve subjective medical necessity disputes or uncovered patients, which the company says it will pursue over time. The distinction frames how much of the collection upside is within management's control. Feeley added that Medicaid is a split story: in states with mature, operationalized coverage, collection rates exceed those in commercial plans, but states without coverage drag down the blend, and GeneDx accepts samples in all 50 states.
Coverage backdrop is supportive but slow to translate. Positive exome policies cover 98% of commercial lives and positive genome policies cover 88%. Medicaid covers genome in 25 states, up from 23, and exome in 37. About 82% of outpatient genome volume was submitted to payers with an active positive policy, up from 67%. Feeley cautioned that payers are often "slow to operationalize" policy changes, and he pushed meaningful Medi-Cal benefit into 2027. Electronic orders, primarily through Epic, show better documentation capture, while most orders still come through GeneDx's own portal.
Guidance: Better Profitability, Revenue at the Low End
Q3 revenue was $123.1 million, including $110.4 million of exome and genome revenue, up $10 million sequentially. More than 32,100 tests were reported. Adjusted gross margin reached 72%, from 69% in Q1 and 70% in Q2, and adjusted net income was $8.6 million, compared with an $8.2 million loss in Q1 and near break-even in Q2.
For the full year, the company raised adjusted gross margin guidance to about 71% and adjusted net income to at least $12 million. It reaffirmed revenue of $475 million to $490 million but said it expects to land at the low end. Q4 guidance calls for total revenue of at least $135 million, exome and genome revenue of $121 million on 34,500 tests, adjusted gross margin of at least 71% and adjusted net income of about $12 million. The Q4 volume guide implies roughly 7% sequential growth, against 4% in Q3.
PAMA Sized, With RCM as the Offset
Feeley provided the first quantification of 2027 Protecting Access to Medicare Act (PAMA) exposure. About 85% of revenue is insurance-based, and a little more than half of those contracts are tied to a percentage of the Clinical Lab Fee Schedule, leaving roughly 45% of total revenue exposed. Separately negotiated fee schedules, which renew on 1-to-3-year cycles, are insulated. Management expects a mid-single-digit headwind to 2027 total revenue, but argues that revenue cycle gains "can more than offset PAMA in the year ahead."
No 2027 guidance was given, and management declined to elaborate beyond saying demand shows no slowdown and that a similar sequential stacking of revenue, aside from typical Q1 seasonality, should recur. The offset thesis relies on an AI-enabled, payer-specific RCM stack that is still being designed. Feeley described Q2 as diagnosis, Q3 as plan validation and architecture, and Q4 into early 2027 as implementation. Investors are therefore being asked to underwrite 2027 collections on tools not yet deployed, a point the company itself stresses when noting that the Q3 collection gain came "without the AI-enabled payer-specific transformation."
Genome Cost Curve and Product Roadmap
Genome cost per test is down 43% from a year ago and, according to Feeley, still carries a few hundred dollars of further reduction over the next several quarters. Reagents, which are the gap between genome and exome, now account for more than half of COGS, and management expects scale and industry sequencing economics to lower them. AI and machine learning on dry-side steps are a second lever, though a more meaningful contributor only in 2027 and beyond. Exome COGS is near optimized and roughly flat versus Q2 and a year ago. Management says dry-side steps are at near parity between the two products, and Feeley added that he is "not sure that all others could say the same."
The company said genome mix should rise again as product enhancements launch and unit economics improve. Long-read sequencing has entered an early access program, with a full launch planned this year and key opinion leaders helping define use criteria. Management declined to size the opportunity. Gardner tied long-read to the company's data moat, noting that de novo variants are often seen in only a handful of patients worldwide and that GeneDx has sequenced more of them "by an order of magnitude." He said the matching of patient profiles "is unique, it is cumulative, and it compounds over time."
Commercial Expansion, Competition and Data Monetization
The General Pediatrics sales force, which entered the field in February, is already "paying for itself" after two quarters. Management expects it to be the largest single contributor to unit volume growth in 2027, and Gardner clarified that this does not mean larger than all other segments combined. Core geneticist and pediatric neurologist growth came mainly from higher productivity per clinician. NICU and prenatal are growing faster than the company overall. Only about 5% of NICU kids are sequenced today, with wide utilization differences across hospitals, and prenatal guidelines lag the science, with chromosomal microarray still the default. Sales force additions in 2027 are expected to be incremental rather than repeating this year's investment, which was driven by the AAP guideline changes. On competition, CEO Katherine Stueland said GeneDx saw no change in competitor behavior in the quarter, despite genome-first and long-read strategies elsewhere. She argued that "competition actually helps us unlock that much larger opportunity" given that the main obstacle is the standard of care itself. Trio testing mix was flat sequentially, with comparator capture reverting to historical norms. Outside diagnostics, the biopharma and data business grew for a second consecutive quarter, adding Mirum Pharmaceuticals and Beren Therapeutics as sponsored testing partners. Management also cited growing interest from AI and ML technology players in the GeneDx Infinity dataset, though no financial detail was provided. The company also hired Nicole Maassen, formerly of Exact Sciences, as Chief Patient Access Officer to lead payer partnerships and government relations.